LT3386500T - Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu - Google Patents

Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu

Info

Publication number
LT3386500T
LT3386500T LTEPPCT/US2016/066023T LT16066023T LT3386500T LT 3386500 T LT3386500 T LT 3386500T LT 16066023 T LT16066023 T LT 16066023T LT 3386500 T LT3386500 T LT 3386500T
Authority
LT
Lithuania
Prior art keywords
benzothiophene
estrogen receptor
selective estrogen
based selective
receptor downregulators
Prior art date
Application number
LTEPPCT/US2016/066023T
Other languages
English (en)
Inventor
Gregory Thatcher
Rui XIONG
Jiong ZHAO
Debra TONETTI
Original Assignee
The Board Of Trustees Of The University Of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Illinois filed Critical The Board Of Trustees Of The University Of Illinois
Publication of LT3386500T publication Critical patent/LT3386500T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
LTEPPCT/US2016/066023T 2015-12-09 2016-12-09 Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu LT3386500T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264971P 2015-12-09 2015-12-09
US201662322878P 2016-04-15 2016-04-15
PCT/US2016/066023 WO2017100712A1 (en) 2015-12-09 2016-12-09 Benzothiophene-based selective estrogen receptor downregulators

Publications (1)

Publication Number Publication Date
LT3386500T true LT3386500T (lt) 2022-12-27

Family

ID=59013340

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/066023T LT3386500T (lt) 2015-12-09 2016-12-09 Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu

Country Status (24)

Country Link
US (7) US20170166551A1 (lt)
EP (2) EP3386500B1 (lt)
JP (2) JP6920709B2 (lt)
KR (1) KR20180088457A (lt)
CN (2) CN108495628B (lt)
AU (1) AU2016366680B2 (lt)
BR (1) BR112018011607B1 (lt)
CA (1) CA3008020C (lt)
DK (1) DK3386500T3 (lt)
EA (1) EA038180B1 (lt)
ES (1) ES2935125T3 (lt)
HR (1) HRP20221462T1 (lt)
HU (1) HUE061065T2 (lt)
IL (1) IL259566B (lt)
LT (1) LT3386500T (lt)
MX (2) MX2018007079A (lt)
NZ (1) NZ743651A (lt)
PL (1) PL3386500T3 (lt)
PT (1) PT3386500T (lt)
RS (1) RS63791B1 (lt)
RU (1) RU2747802C2 (lt)
SI (1) SI3386500T1 (lt)
WO (2) WO2017100712A1 (lt)
ZA (2) ZA201803422B (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3386500B1 (en) 2015-12-09 2022-09-07 The Board of Trustees of the University of Illinois Benzothiophene-based selective estrogen receptor downregulators
US10599150B2 (en) 2016-09-29 2020-03-24 The Charles Stark Kraper Laboratory, Inc. Autonomous vehicle: object-level fusion
MX2019008158A (es) * 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
CA3052810A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
JP2020526492A (ja) 2017-06-29 2020-08-31 ジー１ セラピューティクス， インコーポレイテッド Ｇ１ｔ３８の形態及びその製造方法
US11759450B2 (en) 2018-02-06 2023-09-19 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
US10741313B1 (en) 2019-02-06 2020-08-11 Eaton Intelligent Power Limited Bus bar assembly with integrated surge arrestor
US11249184B2 (en) 2019-05-07 2022-02-15 The Charles Stark Draper Laboratory, Inc. Autonomous collision avoidance through physical layer tracking
WO2021007330A1 (en) * 2019-07-08 2021-01-14 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
CN115710248A (zh) * 2022-11-18 2023-02-24 南京中医药大学 新型选择性雌激素受体下调剂化合物、制备方法及用途

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE4126999A1 (de) 1991-08-16 1993-02-18 Basf Ag Herbizide mittel, enthaltend 3-aminobenzo(b)thiophene als antidots
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
JPH05345780A (ja) * 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
SK280617B6 (sk) 1992-01-16 2000-05-16 Hoechst Aktiengesellschaft Arylcykloalkylové deriváty, spôsob ich prípravy, f
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
EP0622673B1 (en) 1993-04-24 1998-02-04 Kodak Limited Photographic colour couplers and photographic materials containing them
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
DE69635254T2 (de) 1995-07-07 2006-07-13 Astrazeneca Ab Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
PL338555A1 (en) * 1997-08-15 2000-11-06 Univ Duke Method of preventing or treating oestrogen-dependent diseases and disorders
ATE263164T1 (de) 1997-10-03 2004-04-15 Lilly Co Eli Bentzothiophene
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
CN1452497A (zh) 2000-07-06 2003-10-29 惠氏公司 Ssri和雌激素制剂的联合药物形式
AU2001271781A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AU2001271706A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Use of substituted indole compounds for treating breast disorders
WO2002003988A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
CA2415052A1 (en) 2000-07-06 2002-01-17 Wyeth Combinations of bisphosphonates, estrogenic agents and optionally estrogens
US6509332B2 (en) 2000-07-06 2003-01-21 Wyeth Methods of treating excessive intraocular pressure
CN1468110A (zh) 2000-07-06 2004-01-14 惠氏公司 他汀类、雌激素药物以及任选雌激素的联合应用
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
US20020022617A1 (en) 2000-07-06 2002-02-21 American Home Products Corporation Methods for increasing nitric oxide synthase activity
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
ES2253691T3 (es) * 2002-07-24 2006-06-01 Eli Lilly And Company Modulares selectivos del receptor de estrogeno basados en dihidrodibenzo(b,e)oxepina, composiciones y procedimientos.
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
JP2005129430A (ja) 2003-10-27 2005-05-19 Konica Minolta Holdings Inc 光電変換材料用半導体、光電変換素子及び太陽電池
FR2862646B1 (fr) 2003-11-20 2006-02-24 Merck Sante Sas Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
NZ548399A (en) 2003-12-15 2011-01-28 Theramex 1-N-phenyl-amino-1H-imidazole derivatives and pharmaceutical compositions containing them
JP2008528496A (ja) 2005-01-21 2008-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ エストロゲン受容体のモジュレーターとして有用な新規な複素環式ベンゾ［ｃ］クロメン誘導体
WO2006084338A1 (en) 2005-02-14 2006-08-17 Bionomics Limited Novel tubulin polymerisation inhibitors
AU2007211840B2 (en) 2006-02-03 2012-03-01 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP1947085A1 (en) 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
WO2009013195A1 (en) 2007-07-25 2009-01-29 F. Hoffmann-La Roche Ag Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
WO2010093578A1 (en) 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
EP2427430B1 (en) 2009-05-04 2014-09-10 The Royal Institution for the Advancement of Learning/McGill University 5-oxo-ete receptor antagonist compounds
CN105063001A (zh) 2009-09-16 2015-11-18 新基阿维罗米克斯研究公司 蛋白激酶复合物和含有该复合物的药物组合物以及它们的用途
CA2798074A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
JP5844376B2 (ja) 2010-10-06 2016-01-13 ジェイファーマ株式会社 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
IN2014DN05869A (lt) * 2012-01-31 2015-05-22 Novartis Ag
EP2828243B1 (en) 2012-03-20 2018-10-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2014019176A1 (zh) 2012-08-01 2014-02-06 华为技术有限公司 用于同步的方法、装置及系统
CN104583099A (zh) 2012-09-05 2015-04-29 皇家飞利浦有限公司 用于饮料的制备的胶囊、设备和方法
EP2911660B1 (en) * 2012-10-24 2019-12-04 The Board of Trustees of the University of Illionis Compositions and methods for treating estrogen-related medical disorders
WO2014066695A1 (en) * 2012-10-24 2014-05-01 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
US8877801B2 (en) * 2013-02-19 2014-11-04 Novartis Ag Compounds and compositions as selective estrogen receptor degraders
EP2970130A4 (en) 2013-03-14 2016-08-03 Seragon Pharmaceuticals Inc MODULATORS OF POLYCYCLIC STROGEN RECEPTORS AND USES THEREOF
SI3004090T1 (en) 2013-05-28 2018-01-31 Astrazeneca Ab Chemical compounds
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
SG11201509508YA (en) 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
RU2016137150A (ru) 2014-03-13 2018-04-18 Ф. Хоффманн-Ля Рош Аг Способы и композиции для модулирования мутантов эстрогеновых рецепторов
MA39741A (fr) 2014-03-13 2017-01-18 Hoffmann La Roche Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
RS64115B1 (sr) 2014-03-28 2023-04-28 Univ Duke Lečenje kancera dojke upotrebom selektivnih modulatora receptora estrogena
JP2017538727A (ja) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
EA032311B1 (ru) 2014-12-18 2019-05-31 Ф. Хоффманн-Ля Рош Аг Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
WO2016189011A1 (en) 2015-05-26 2016-12-01 F. Hoffmann-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
AU2016279330B2 (en) 2015-06-16 2020-05-14 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
JP6776348B2 (ja) 2015-10-01 2020-10-28 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物
WO2017056115A1 (en) 2015-10-03 2017-04-06 Sun Pharma Advanced Research Company Limited Novel n-aryl containing fused heterocyclic compounds
JP2018533561A (ja) 2015-10-07 2018-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト （ｅ）−３−（４−（（ｅ）−２−（２−クロロ−４−フルオロフェニル）−１−（１ｈ−インダゾール−５−イル）ブタ−１−エン−１−イル）フェニル）アクリル酸を調製するためのプロセス
RS63217B1 (sr) 2015-10-27 2022-06-30 Sun Pharma Advanced Res Co Ltd Novi heterociklični antiestrogeni
CN108349952A (zh) 2015-11-09 2018-07-31 豪夫迈·罗氏有限公司 四氢萘雌激素受体调节剂及其用途
US10519148B2 (en) 2015-11-12 2019-12-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
EP3386500B1 (en) * 2015-12-09 2022-09-07 The Board of Trustees of the University of Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.

Also Published As

Publication number Publication date
RU2018125046A (ru) 2020-01-09
CN108699024A (zh) 2018-10-23
US10118910B2 (en) 2018-11-06
PT3386500T (pt) 2023-01-06
WO2017100712A1 (en) 2017-06-15
RU2747802C2 (ru) 2021-05-14
IL259566B (en) 2021-09-30
US20170166550A1 (en) 2017-06-15
CA3008020C (en) 2024-02-20
SI3386500T1 (sl) 2023-01-31
CN108699024B (zh) 2022-03-11
US20210047286A1 (en) 2021-02-18
KR20180088457A (ko) 2018-08-03
JP2021169498A (ja) 2021-10-28
WO2017100715A1 (en) 2017-06-15
BR112018011607A2 (pt) 2018-11-27
MX2020006991A (es) 2022-07-14
EP3386500A1 (en) 2018-10-17
ZA201803422B (en) 2020-08-26
US10807964B2 (en) 2020-10-20
NZ743651A (en) 2023-07-28
MX2018007079A (es) 2018-11-12
BR112018011607B1 (pt) 2024-01-30
US20220194917A1 (en) 2022-06-23
CA3008020A1 (en) 2017-06-15
HUE061065T2 (hu) 2023-05-28
CN108495628B (zh) 2022-01-11
EP3386968A4 (en) 2019-09-25
RU2018125046A3 (lt) 2020-02-10
US20200079752A1 (en) 2020-03-12
EP3386500B1 (en) 2022-09-07
DK3386500T3 (da) 2022-12-12
IL259566A (en) 2018-07-31
ZA202003023B (en) 2022-12-21
US11072595B2 (en) 2021-07-27
EA038180B1 (ru) 2021-07-20
AU2016366680B2 (en) 2021-06-24
US11447461B2 (en) 2022-09-20
US10377735B2 (en) 2019-08-13
JP6920709B2 (ja) 2021-08-18
PL3386500T3 (pl) 2023-03-13
CN108495628A (zh) 2018-09-04
US20200123126A1 (en) 2020-04-23
ES2935125T3 (es) 2023-03-01
EA201891376A1 (ru) 2019-02-28
HRP20221462T1 (hr) 2023-01-20
EP3386968A1 (en) 2018-10-17
AU2016366680A1 (en) 2018-07-12
EP3386500A4 (en) 2019-05-22
JP2019502675A (ja) 2019-01-31
US20190055209A1 (en) 2019-02-21
RS63791B1 (sr) 2022-12-30
US20170166551A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
ZA202003023B (en) Benzothiophene-based selective estrogen receptor downregulators
GB201514875D0 (en) Receptor
HK1252163A1 (zh) 受體
GB201522592D0 (en) T cell receptors
HK1253695A1 (zh) T細胞受體特異性抗體
HK1256799A1 (zh) 集成的開關濾波器網絡
SG11201708313QA (en) T cell receptor
GB201702617D0 (en) Receptor
HK1256291A1 (zh) 衛生潔具沖水系統
PL3529267T3 (pl) Receptor komórek t
EP3350167A4 (en) Androgen receptor Antagonist
PL3155011T3 (pl) Mutacje receptora hormonu glikoproteinowego
GB2542922B (en) Support Harness
GB2528775B (en) Mixing device
GB2544560B (en) Mixing bowl
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
PL3500265T3 (pl) Selektywne ligandy receptora estrogenowego beta
GB201518991D0 (en) T cell receptors
HUE052830T2 (hu) Keverõszerkezet
GB201520136D0 (en) Fixing device for chairs
GB201515020D0 (en) Seat
GB201504285D0 (en) Receptor modulation
HUP1500233A2 (hu) Volfrám alapú metatézis katalizátorok
AU361668S (en) A swinging seat